IDEX BIOMETRICS ASA
Oslo, Norway, 7 January 2021: IDEX Biometrics ASA (OSE: IDEX and OTCQB: IDXAF) is a leading provider of advanced fingerprint identification and authentication solutions. CEO Vince Graziani and CFO Derek D’Antilio will participate at the 23rd Annual Needham Growth Conference on Wednesday 13 January 2021, which is being held as a virtual event.
Portfolio managers and analysts who would like to request a meeting with management should contact their Needham representative (conferences@needhamco.com ) or IDEX’s investor relations.
About IDEX Biometrics
IDEX Biometrics ASA is a leading provider of fingerprint identification technologies offering simple, secure and personal touch-free authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings. We invent, engineer, and commercialize these secure and safe yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics
U.S. Investor Contact:
Brett L Perry, Shelton Group
E-mail: sheltonir@sheltongroup.com
Tel: +1 214 272 0070
Company Contacts:
Marianne Bøe, Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: + 47 918 00186
Derek D’Antilio, Chief Financial Officer
E-mail: derek.dantilio@idexbiometrics.com
Tel: +1 978 273 1344
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S21.6.2025 01:38:10 CEST | Press release
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Novo Nordisk A/S21.6.2025 01:34:39 CEST | Press release
Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Meeting Professionals International (MPI)21.6.2025 01:30:16 CEST | Press release
MPI Shares WEC 2025 Highlights, Announces Strategic Growth and New Offerings at Annual Press Conference
Leading Edge Materials Corp.20.6.2025 23:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO APRIL 30, 2025
Aduro Clean Technologies Inc.20.6.2025 22:33:57 CEST | Press release
Aduro Clean Technologies Announces Closing of Underwriter’s Over-Allotment Option in Public Offering
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom